International Trade Today is a service of Warren Communications News.
Subscriber Login

EAPA Litigation

Under the Enforce and Protect Act, CBP investigates whether a company is evading particular antidumping and countervailing duty orders. Litigation on determinations made under the relatively new statute have centered on due process protections for respondents, CBP's evidentiary basis for its decisions and the interplay of decisions made on the scope of the applicable AD/CVD orders from both CBP and the Commerce Department. The Court of Appeals for the Federal Circuit issued a key decision for all EAPA cases in Royal Brush Manufacturing v. United States, when it found CBP to have violated a respondent's due process protections by failing to provide it with access to the business proprietary information used in the proceeding. 

to
Refine Category Search
Clear Terms

Search Primer

Multi-word term: Place inside quotes to ensure an exact match together (e.g. "China import").

Term list: Separate terms with spaces, not commas or semicolons to find either word (e.g. AD/CVD antidumping).

Acronyms: Use all capital letters (e.g., ACE).

Required term: If a term must be included in any resulting articles, prefix it with a plus sign (e.g., CBP +releases).

Excluded term: If a term should be excluded from any articles being found, prefix it with a minus sign (e.g., -ruling).

Singular form: Use the singular form when doing multi-word terms (e.g. "russian export control" instead of "russian export controls").

Shortest word form: When you have different word forms in a quoted term, include the shortest version if it is the last part of the expression (e.g., "entity list" instead of "entity listing" or "entity listed").

FDA Watching Medical Supply Chain Closely for Coronavirus Disruptions
February 28, 2020 |FDA

The Food and Drug Administration “has been closely monitoring the supply chain with the expectation that the COVID-19 [coronavirus] outbreak would likely impact the medical product supply chain, including potential disruptions to supply or shortages of critical medical products in the U.S.,” FDA Commissioner Stephen Hahn said in a news release. The agency has communicated with more than 180 drug manufacturers to remind them about notification requirements for supply disruptions, it said. “Also, as part of our efforts, the FDA has identified about 20 other drugs, which solely source their active pharmaceutical ingredients or finished drug products from China,” it said. “We have been in contact with those firms to assess whether they face any drug shortage risks due to the outbreak. None of these firms have reported any shortage to date. Also, these drugs are considered non-critical drugs.”

FDA Extends Comment Period on Proposal to Require Testing by Accredited Labs to Prove Admissibility
February 27, 2020 by Brian Feito|FDA

The Food and Drug Administration is extending the comment period on its proposal (see 1911060035) for a new accreditation scheme for food testing laboratories that would require importers to use accredited laboratories in some circumstances, including getting food they import off import alerts and proving admissibility of food that is initially refused admission. The comments are due April 6.

FDA Inspections Halted in China, but No Direct Public Health Risk From Imports, Agency Says
February 25, 2020 by Brian Feito|FDA

Imports do not pose a higher public health risk as a result of the ongoing COVID-19 (coronavirus) outbreak, the Food and Drug Administration said in a Feb. 24 statement. “There is no evidence to support transmission of COVID-19 associated with imported goods and there have not been any cases of COVID-19 in the United States associated with imported goods,” FDA said, though it noted that “this remains a dynamic situation and we will continue to assess, and update guidance as needed.”